| Similar Articles |
|---|
 |
Chemistry World
November 5, 2012
Andrew Turley |
Approval for first gene therapy drug Alipogene tiparvovec, marketed as Glybera, has become the first gene therapy drug to win approval in either the US or the EU.   |
Chemistry World
November 3, 2015
Phillip Broadwith |
Bristol-Myers Squibb to buy Cardioxyl for heart drug The deal gives BMS full rights to develop CXL-1427, an experimental drug for acute decompensated heart failure, currently in Phase II clinical trials. |
Chemistry World
July 29, 2015
Phillip Broadwith |
Biogen to develop gene therapies with AGTC The deal covers AGTC's development programs for several rare eye diseases using a viral-based gene delivery vector. |
Chemistry World
January 11, 2016
Phillip Broadwith |
GSK's ViiV to buy HIV drugs from BMS Bristol-Myers Squibb has agreed to sell its entire portfolio of investigational HIV drugs as the company seeks to exit research in virology. |
Scientific American
September 2009
Melinda Wenner |
Gene therapy: An Interview with an Unfortunate Pioneer Lessons learned by James M. Wilson, the scientist behind the first gene therapy death |
BusinessWeek
April 22, 2010
Rob Waters |
Gene Therapy Takes a Turn for the Better Researchers and investors are heartened by advances in gene therapy. Analysts say revenues are still several years off, however. |
Salon.com
June 1, 2000
Tabitha M. Powledge |
Gene therapy R.I.P.? When the country's biggest gene therapy institute was ordered to stop testing on humans last week, the action marked the end of an era fraught with dubious claims to success and a mess of unreported adverse effects. |
Pharmaceutical Executive
August 1, 2005
Joanna Breitstein |
Weathering the Storm Out from financial scandal, CEO Peter Dolan is steering Bristol-Myers Squibb's most productive pipeline yet. |
HHMI Bulletin
Aug 2011 |
Seeing is Believing Today, researchers are finding clever ways to deliver long-lasting, healthy genes without triggering a serious immune response. |
BusinessWeek
March 6, 2006
Bruce Einhorn |
A Cancer Treatment You Can't Get Here China, with lower regulatory hurdles, is racing to a lead in gene therapy. |
Chemistry World
December 20, 2013
Patrick Walter |
AstraZeneca shells out $4.1bn for diabetes business AstraZeneca has agreed to pay Bristol-Myers Squibb up to $4.1 billion for its share of the pharma giants' diabetes joint venture. |
The Motley Fool
July 30, 2007
Brian Orelli |
Another Blow to Gene Therapy The FDA shuts down a clinical trial, tripping up Targeted Genetics and possibly its competitors. A subject in the trial of their gene therapy arthritis medication died shortly after taking the drug. |
Chemistry World
January 3, 2013
Sarah Houlton |
2012 pharma industry roundup It may have been a relatively quiet year in terms of mergers and acquisitions, but the pharma industry nonetheless made plenty of headlines in 2012. |
Pharmaceutical Executive
February 1, 2006
Ron Feemster |
Gene Logic: Rescue Squad One or two late-stage clinical failures can land promising drug candidates on the shelf. Forever? Maybe not. Gene Logic tests Big Pharma's dead drugs for hundreds of different targets. |
Chemistry World
October 7, 2015
Phillip Broadwith |
Bristol-Myers-Squibb fined for alleged Chinese bribes The US Securities and Exchange Commission has fined New York based pharmaceutical company Bristol-Myers Squibb over $14 million over alleged bribes made to Chinese state owned hospitals. |
Chemistry World
March 14, 2014
Phillip Broadwith |
Bristol-Myers Squibb to close Irish plant BMS tied the closure to 'changing market demand' for its products, along with efforts to optimize its manufacturing network. |
Chemistry World
April 4, 2013
Phillip Broadwith |
Amylin headquarters to close with further job losses Bristol-Myers Squibb has confirmed that it will be closing the site in San Diego, US, which was formerly the corporate headquarters of biotech firm Amylin. |
